What Is the Global Immunotherapy Coalition (GIC)?
The Global Immunotherapy Coalition, or GIC, comprises of multinational pharmaceutical groups, biotechnology companies, major academic cancer centers and community oncologists. This unprecedented collaboration will make possible access to over 60 novel and approved agents under exploration in the war against cancer, and will enable rapid testing of novel immunotherapy protocols, forming the basis of Cancer Breakthroughs 2020.
Who Is Involved in the GIC and the Cancer Breakthroughs 2020 Program?
The Global Immunotherapy Coalition, or GIC, is comprised of multinational pharmaceutical groups including Celgene (Robert J. Hugin, Chairman and CEO) and Amgen (Paul Seligman, M.D., MPH, Chief of R&D Policy); biotech including NantWorks (Dr. Patrick Soon-Shiong, M.D., Founder and CEO) and NantKwest (Dr. Patrick Soon-Shiong, M.D., Chairman and CEO), Etubics (Frank R. Jones, Ph.D., Chairman, President, and CEO); Altor Bioscience (Hing C. Wong, Ph.D., CEO and Founder), and Precision Biologics (Philip M. Arlen, M.D., CEO); major academic cancer centers and community oncologists (including Johns Hopkins, Tufts, and Columbia); and Communications technology including Allscripts (Paul M. Black, CEO and Director) and Blackberry (John Chen, CEO).
This historic alliance--in collaboration with Independence Blue Cross (Daniel J. Hilferty, President and Chief Executive Officer), one of America's largest payers; and Bank of America (Jim Huffman, Senior Vice President, Head of US Health and Wellness Benefits), one of the largest self-insured companies in the U.S. —has come together with a singular focus: accelerating the potential of combination immunotherapies as the next generation standard of care in patients with cancer.